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and FISH genetic test costs, re-biopsy cost, probability of progression while on pem-
etrexed treatment and probability of re-biopsy. ConClusions: EML4–ALK genetic 
testing in combination with crizotinib treatment for all NSCLC patients eligible for 
chemotherapy is not economically attractive in the current setting. Lower drug costs 
would be required to make this strategy economically feasible.
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objeCtives: Compare the costs and effectiveness of a nonpharmacologic interven-
tion, mindfulness-based art therapy (MBAT) aimed at psychological stress reduc-
tion for women with breast cancer. Methods: Participants were randomized into 
three groups: MBAT, Usual Breast Cancer Support (BCSG), or Untreated Control (UC). 
The MBAT intervention involved mindfulness-based stress reduction techniques 
along with art therapy. BCSG provided didactic lectures and discussion among par-
ticipants. Each group attended programs for 8 weeks, for 2 ½ hours each week. 
Follow-up was done at 9 weeks. Health care costs due to psychological problems 
were captured in the form of health care utilization, including outpatient calls to 
physicians, outpatient visits, emergency room visits, and inpatient admissions, 
as well as cost of medications. Effectiveness was measured using health utility 
deduced from the Medical Outcomes Study 36-Item Short Form Health Survey (SF-
36). Results: The number of women in each group was: 98 completing MBAT, 93 
completing BCSG, 44 UC. Mean health care costs due to psychological problems 
decreased at 9 weeks in the MBAT group (from $98.96/month to $0.00/month), 
increased in BCSG (from $3.60/month to $32.06/month), and stayed consistent with 
no health care utilization in UC. Medication costs decreased in all 3 groups at 9 
weeks (MBAT: $50.23/month to $6.40/month; BCSG: $48.87/month to $13.69/month; 
UC: $46.80/month to $24.63/month). Health utility (mean,SD) increased at week 9 in 
all groups: MBAT from 0.47(.085) to 0.50(.076); BCSG from 0.50(.086) to 0.52(.084); UC 
from 0.52(.086) to 0.55(.058). ConClusions: All groups experienced similar utility 
improvements at 9 weeks, suggesting that the decision as to whether to choose 
MBAT, BCSG, or UC should be based on costs. However, these data are short-term 
and should be interpreted cautiously since sustained quality of life is important 
to the decision. Findings suggest that MBAT may reduce health care costs due to 
psychological problems but a larger sample is necessary to confirm this.
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objeCtives: To assess the cost-effectiveness of first line metastatic renal cell 
cancer (mRCC) drugs from the perspective of two different economic and clinical 
settings, The Netherlands (NL) and Serbia (SRB). Methods: The research included 
all first line mRCC therapeutics recommended by the European and American 
guidelines: sunitinib, pazopanib, bevacizumab and temsirolimus. Clinical efficacy 
data were extracted from published pivotal and head-to-head studies. Costs were 
described with regards to the treatment protocols of NL and SRB. A Markov model 
was designed to incorporate efficacy and costs data per each therapeutic alterna-
tive. An annual discount rate of 1.5% for health and 4% for costs was applied and 
a health care perspective was taken. Probabilistic sensitivity analysis (PSA) was 
performed to test the uncertainty around the base-case estimate. Results: With 
the incremental cost-effectiveness ratio (ICER) of € 44,512 and € 39,625/QALY in NL 
and SRB respectively, sunitinib was the most cost-effective therapeutic alternative, 
followed by pazopanib, temsirolimus and bevacizumab. Incremental costs were 
comparable in SRB and NL and mainly controlled by the drugs’ price. All estimated 
ICERs appeared lower within Serbian economic surrounding. PSA revealed a wide 
confidence interval around the base-case ICERs highly dependent on potential 
gain in overall survival (OS). ConClusions: The base-case ICERs calculated for NL 
were below the commonly accepted threshold recommended by WHO (three times 
national GDP per capita for QALY or € 95,700/QALY in NL), indicating the relative cost-
effectiveness of examined mRCC drugs. However, none of these pharmaceuticals 
could be regarded as cost-effective under the same criterion in SRB (threshold of 
€ 14,400/QALY). Although between-the-setting variation resulted in lower ICERs in 
SRB, this could not compensate for the sevenfold difference in countries’ incomes. 
Finally, two main parameters that might increase cost-effectiveness of mRCC drugs 
in mid-income countries seem to be the drug prices and their potential benefit in OS.
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objeCtives: Cost-effectiveness of pazopanib versus sunitinib in Egyptian patients 
with metastatic renal cell carcinoma has not yet been established. The aim of the 
present study was to evaluate the cost-effectiveness of pazopanib versus sunitinib 
in Egyptian patients with metastatic renal cell carcinoma over a ten-year period 
from the perspective of the health insurance. Methods: A cohort Markov chain 
model with three health states (first line until progression, progression, and death) 
based on Egyptian clinical practice was derived from published sources. The length 
of a cycle was set at six weeks. The clinical parameters were derived from rand-
omized trial previously published. The quality of life of the health states was derived 
using the available published data. Direct medical costs were obtained from the 
health insurance tariff in Egypt. All costs and effects were discounted at 3.5% annu-
objeCtives: mCRPC is a terminal disease, with a median survival of approximately 
1 to 2 years. The AFFIRM study demonstrated that enzalutamide is highly effica-
cious, prolonging overall survival and progression-free survival compared to placebo 
in patients with mCRPC previously treated with docetaxel-based chemotherapy. 
The purpose of this analysis is to assess from the Canadian perspective the cost-
effectiveness of enzalutamide 160mg once-daily compared with abiraterone acetate 
(AA) (+ prednisone) and intravenous (IV) cabazitaxel in mCRPC patients previously 
treated with docetaxel-based chemotherapy. Methods: A Markov model was 
developed to capture time spent by patients in various health states, including 
progression, progression free survival (PFS) and death. Results were reported as 
incremental costs per additional quality adjusted life-years (QALY) gained over a 
10-year period. Transition probabilities were derived from patient-level data from 
AFFIRM and an indirect treatment comparison from available published literature. 
The base case analysis focused on direct medical costs from the perspective of the 
Canadian Ministry of Health (MoH), with the second analysis focusing on the societal 
perspective. Cost data for 2013, obtained from a variety of sources were reported 
as Canadian Dollars. A 5% discount rate was applied to both costs and patient out-
comes. Multiple sensitivity analyses were undertaken to test the robustness of the 
model Results: From the MoH perspective, enzalutamide had an incremental cost-
utility ratio (ICUR) of $42,325 and $43,105 per additional QALY gained compared to 
AA and cabazitaxel, respectively. Results were similar from the societal perspective. 
Results were robust over a wide range of one-way and probabilistic sensitivity analy-
ses. In greater than 85% of iterations the incremental cost-effectiveness ratio ICER 
was below a willingness-to-pay threshold of $100,000 per QALY for the comparison 
versus either AA or cabazataxel. ConClusions: Enzalutamide is a cost-effective 
treatment compared to AA and cabazitaxel in mCRPC patients previously treated 
with docetaxel-based chemotherapy
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objeCtives: We estimated the incremental cost-utility of newer chromogenic or 
silver in situ hybridization (CISH, SISH) techniques vs. fluorescence-based meth-
ods (FISH) to diagnose human epidermal growth factor receptor-2 positive (HER2+) 
breast cancer (BC) and direct targeted adjuvant trastuzumab using decision-analytic 
modelling. Newer CISH and SISH may be more widely useful in pathology prac-
tice owing to the use of light (vs. fluorescence) microscopy. Methods: A decision 
tree represented 6 alternative test-treat strategies to direct adjuvant trastuzumab 
in HER2+ early-stage BC. The strategies consisted of primary CISH, FISH or SISH 
testing, or, primary immunohistochemistry (IHC) with CISH, FISH or SISH con-
firmation of IHC equivocal results only. We assumed FISH as gold standard, with 
trastuzumab treatment for IHC+ or FISH+. A Markov model of early-stage BC esti-
mated the sequela of treatment based on test results by accounting for true HER2 
status in the lifetime horizon from the payer’s perspective. Treatment effect and test 
accuracy parameters were informed by meta-analyses. Uncertainty was character-
ized using probabilistic sensitivity analyses and cost-effectiveness acceptability 
curves. Results: Primary FISH testing was dominant in the base case, assuming 
20% HER2+ disease prevalence, decreasing costs by a mean of $815 and improving 
outcomes by 0.0022 QALYS compared to the referent strategy of primary IHC with 
FISH confirmation of IHC equivocal results. After HER2+ disease prevalence, results 
were most sensitive to test sensitivity and specificity parameters. Primary FISH, 
CISH or SISH strategies had higher probabilities of being cost-effective than primary 
IHC strategies. ConClusions: Our results suggest that the additional costs of pri-
mary in situ hybridization testing are offset in the long-term by improved health 
outcomes. The significant uncertainty attributed to test accuracy parameters sug-
gests that additional research is needed to determine whether newer CISH or SISH 
can perform equivalently to FISH for HER2 status determination.
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objeCtives: Targeted therapy with ALK inhibitor crizotinib offers significant 
improvement in clinical outcome for treatment of EML4–ALK fusion positive non-
small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of 
companion EML4-ALK genetic testing in combination with crizotinib treatment in 
the second-line setting for advanced NSCLC in Ontario. Methods: We performed 
a cost-effectiveness analysis using a Markov model from a Ministry of Health per-
spective and a lifetime horizon. Transition probabilities and mortality rates were 
calculated based on the data of a recent second-line randomized trial of crizotinib 
versus chemotherapy (Shaw et al. New Engl J Med 2013). Costs were obtained from 
OCCI database, public labs and Princess Margaret Hospital. All parameters were 
varied separately in one-way and selected two-way sensitivity analyses. Various 
scenarios to assess the impact of model assumptions about testing and treatment 
were conducted. Results: The use of pemetrexed and docetaxel in ALK-rearranged 
NSCLC, based on our preliminary model, could yield as much as 0.539 QALY and 
0.429 QALY respectively, assuming no crossover from chemotherapy to crizotinib. 
Average costs per patient based on the preliminary model are estimated at CAD 
$19,388 for pemetrexed and $$33,226for docetaxel, with incremental cost-effective-
ness ratios of $333,595/QALY and $125,812/QALY gained respectively. The results of 
the one-way sensitivity analysis indicated that the primary drivers of the ICER were 
the utilities and cost of crizotinib treatment. The model was least sensitive to IHC 
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A91
deviate from practice guidelines. We compared observed clinical testing and treat-
ment practices to practices that follow guidelines to target adjuvant trastuzumab 
in HER2+ BC using cost-utility analysis. Methods: We used a probabilistic decision 
tree linked to a Markov model to estimate the incremental cost-utility of 2 alterna-
tive test-treat strategies to target adjuvant trastuzumab in Canadian BC patients; 
primary fluorescence in situ hybridization (FISH) vs. primary immunohistochem-
istry (IHC) with FISH confirmation with trastuzumab treatment for all FISH+ or 
IHC+. The BC Markov model was calibrated against Canadian BC registry mortality. 
Population-level observational data informed model probabilities of confirmatory 
FISH testing, probabilities of treatment based on test results, and HER2+ disease 
prevalence under the current practice scenario. Uncertainty was characterized 
using deterministic and probabilistic sensitivity analyses and cost-effectiveness 
acceptability curves (CEACs). Results: In the base case analysis assuming 20% 
HER2+ disease prevalence and perfect adherence to testing and treatment guide-
lines, primary FISH testing was dominant; it decreased costs by a mean of $815 and 
improved outcomes by 0.0022 QALYS compared to the strategy of primary IHC with 
FISH confirmation of equivocal results. Health outcomes were poorer in simula-
tions of current testing and treatment practice. Results were sensitive to HER2+ 
disease prevalence rate, test accuracy, treatment benefit carryover and testing 
behaviors. ConClusions: Improved adherence to treatment guidelines combined 
with primary FISH testing could improve long-term outcomes and costs in practice. 
Local disease epidemiology should be considered when formulating personalized 
medicine policies. Scenario analyis comparisons of guideline adherent vs. practice 
patterns derived from observational data can provide important insights into the 
consequences of deviations from practice when forming policy.
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eveNts iN ChroNiC myeloid leukemia (Cml) BraziliaN PatieNts
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objeCtives: This research aimed to estimate the standard of resource use 
and its cost associated of treating CML patients, considering hematological 
and non-hematological adverse events grades 3-4 from the perspective of the 
Brazilian National Health System. Cost of treatment per event was generated 
as a result. Methods: A Delphi methodology was applied in Brazil to study the 
management of adverse events related to CML by collecting data on resource 
used and estimating costs associated. Ten experts completed the questionnaires 
developed and the results were compiled and validated. The data collected were 
related to the percentage of patients affected by each AE and to the resource 
used for management. The unit cost of resources was based on the Price Bank 
System (SUS-SIGTAP). Cost of treatment considered treatment options and moni-
toring (e.g., outpatient visits, laboratory tests, procedures, hospitalizations) in 
the Brazilian Public Health System. Results: Among non-hematologic adverse 
events, gastrointestinal bleeding and central nervous system (CNS) hemorrhage 
presented the highest costs of treatment (R$ 1.022,90 and R$ 1.173,34, respectively). 
Hospitalization was the resource with more impact; mainly in CNS hemorrhage, 
with an average length of hospitalization reported by the experts of 1 week and 
also demanded by 100% of patients affected by this AE. Management of cardiac 
events and pericardial effusion was R$973,35 and R$3.896,55. Cytopenias are the 
most commonly events in patients with CML receiving BCR–ABL inhibitors; experts 
suggested use of growth factors in patients with CML receiving TKI therapy. Costs 
associated with the management of hematologic adverse events are: Anemia: 
R$14,93, Thrombocytopenia: R$14,47 and neutropenia: R$211,54. ConClusions: 
Adverse event management in CML patients has important economic impact All 
adverse events related to treatment of CML, with differences in the occurrence 
and intensity should be valued and recorded as contributing to the estimative of 
total cost of treating the disease.
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objeCtives: Examine health care cost and utilization among patients diagnosed 
with metastatic colorectal cancer (mCRC) or Gastrointestinal stromal tumor (GIST) 
prior to being treated with Stivarga® (regorafenib). Methods: Adult patients 
treated with Stivarga from 9/27/12-7/31/13 were identified from a large national US 
claims database. Patients were retained if they were continuously enrolled in the 
health plan for at least 6 months before the initial (index) diagnosis and 1 month 
after the index diagnosis. Patients were required to be diagnosed with mCRC or GIST, 
be 18+ years old, and have non-missing demographic information. Health care cost 
and utilization was examined during 2 time periods; 1) the 6 months immediately 
preceding the index fill (fixed baseline) and 2) the entire variable length period pre-
ceding the index fill (variable baseline). Cancer-related cost and utilization included 
claims with a diagnosis of cancer. Results: 283 patients were treated with Stivarga 
and 235 met all inclusion criteria. Mean age was 61.6 years, 66.4% were female, and 
38.7% were Medicare Advantage patients. Mean length of baseline enrollment was 
4.2 years (median: 3.3 years). In the 6-month baseline period, 41.3% of patients had 
an ER visit and 34.0% had an inpatient stay (IP); 18.7% and 32.8% had a cancer-related 
ER visit and IP stay, respectively. On average, patients had 35.8 ambulatory visits; 
27.8 were cancer-related. Mean 6-month health care cost was $78,771 ($6,559 phar-
macy, $72,212 medical); the majority of medical costs were cancer-related ($68,866). 
Cancer-related ambulatory services and IP stays accounted for $57,814 and $9,713, 
respectively. In the variable baseline, cancer-related medical costs were $314,410 
with $240,544 in ambulatory costs. The cost of all chemotherapy (oral and adminis-
tered) was $168,386. ConClusions: Patients treated with Stivarga incur significant 
health care cost and utilization, accounting for over $18.5 million in health care cost 
in the 6 months prior to initiating Stivarga.
ally. All costs were reported in Egyptian pounds of the financial year 2013. Results: 
The total quality-adjusted life-years (QALYs) of pazopanib was estimated to be 725 
and that for sunitinib was 674, which resulted in a difference of 51 QALYs. The total 
costs for pazopanib and sunitinib were EGP 2,692,116 and EGP 3,712,660, respectively 
(the difference was -1,020,543), which yielded an incremental cost-effectiveness 
ratio of EGP -19,946/QALY. Thus, pazopanib was superior. Various one-way sensi-
tivity analyses indicated that the overall survival medians of both drugs had the 
greatest effects on the results. ConClusions: The present study concludes that, 
from the perspective of the health insurance, pazopanib is more effective and less 
costly than sunitinib for patients with metastatic renal cell carcinoma. This model 
addresses both the health and economic implications of both drugs. These results 
suggest that pazopanib is the superior therapy. This study helps to inform decisions 
about the allocation of health care system resources and to achieve better health 
in the Egyptian population.
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Cost-utility aNalysis of Coffee CoNsumPtioN for PreveNtioN of 
ChroNiC disease aNd CaNCer iN the uNited states
O’Day K, Campbell C.M., Popelar B.V.
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objeCtives: Coffee (Coffea arabica) is one of the most widely consumed beverages 
worldwide. Epidemiologic studies suggest coffee may prevent some chronic diseases 
and cancers. This study aims to assess the cost-utility of coffee consumption from 
a US consumer perspective. Methods: A cohort life-table analysis was developed 
to model life years (LYs) and quality-adjusted life years (QALYs) of coffee drink-
ers versus non-drinkers over a lifetime horizon. Age- and sex-specific incidence 
and mortality rates were used to model outcomes of chronic disease (Alzheimer’s, 
depression/suicide, diabetes, heart failure, Parkinson’s, stroke) and cancer (blad-
der, breast, colorectal, endometrial, esophageal, leukemia, liver, oral, pancreatic, 
prostate). Relative risks of chronic diseases and cancers by cups of coffee consumed 
daily were obtained from meta-analyses of prospective cohort and case-control 
studies. Utility weights, baseline health care costs, and attributable disease costs 
were obtained from the literature. Costs per cup of coffee were estimated for home 
preparation and obtained from a national sample of low- and high-cost vendors. 
Incremental analyses were conducted by dose, cost, and sex. The model was vali-
dated by comparing predicted life-expectancy to data from studies examining all-
cause mortality of coffee consumption. Probabilistic sensitivity analyses (PSA) were 
conducted. Results: Coffee increased undiscounted LYs in 2, 4, and 6 cup/day male 
(0.29, 0.52, 0.70) and female (0.31, 0.54, 0.69) drinkers, respectively, compared to 
non-drinkers. Home preparation resulted in ICERs per discounted QALY of $36,031, 
$44,125, and $55,572 for male and $31,029, $37,779, and $46,280 for female drink-
ers, respectively, for 2, 4, and 6 cups/day. ICERs were higher for coffee purchased 
from low-cost vendors (> $50,000/QALY) and high-cost vendors (> $80,000/QALY). 
In the PSA, 4 and 6 cups/day were most likely cost-effective for males and females, 
respectively, at a $50,000/QALY threshold. ConClusions: Coffee consumption may 
be a cost-effective approach to improve health outcomes. Given the limitations of 
observational effectiveness data, additional research is warranted.
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objeCtives: Compare demographic and clinical characteristics among colorectal 
cancer (CRC) patients with different treatment lines (TL) in the U.S. veteran popula-
tion. Methods: Adult patients with at least one administration of CRC treatment 
were selected from the U.S. Veterans Health Administration database (01APR2006-
30SEP2012). The first observed treatment date was designated as the index date. 
Patients were required to have continuous pharmacy and medical benefits at least 
6 months pre-index date (baseline) and were followed until the earliest of death, 
or end of enrollment or study period. At least one primary CRC diagnosis code was 
required during the baseline period. Four cohorts were created based on the number 
of TL. Demographic and clinical characteristics were compared among patients with 
one, two, three, or four TL using appropriate statistical tests. Results: A total of 
11,078 patients were included in the study sample (63% with one TL; 22% with two 
TL; 8% with three TL; 7% with four TL). Patients treated with three or four TL were 
similar in age (3 TL: 63.8 years; 4 TL: 63.3) but significantly younger compared to 
patients with one or two lines (1 TL: 67.0; 2 TL: 64.6). Patients with 3 or 4 TL had a 
lower Chronic Disease Score, and lower rates of hypertension and stroke. During the 
6-month baseline period, patients with 1 TL had much longer hospitalization stays 
and a higher rate of inpatient visits (7.3 days, 57.4%) compared to patients in other 
cohorts. A similar trend was found in baseline health care costs, where patients 
with 1 TL incurred the highest costs ($38,010) compared to the other three cohorts 
(2 TL: $34,332; 3 TL: $33,738; 4 TL: $31,120; all p-values< 0.002). ConClusions: CRC 
patients with more than two TL were younger and had less comorbid conditions 
than patients with one or two TL.
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objeCtives: Observational research suggests that personalized medicine practices 
in human epidermal growth factor receptor-2 positive (HER2+) breast cancer (BC) 
